We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current LC8 market cap is 1.09B. The company's latest EPS is SEK -7.8255 and P/E is -0.96.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 184.83M | 874k | 229.35M | 802.88M | 1.21B |
| Operating Income | -27.88M | -382.22M | -522.84M | -414.81M | -409.42M |
| Net Income | -32.58M | -433.49M | -500.29M | -412.27M | -466.19M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 845.2M | 1.51B | 1.46B | 1.95B | 1.86B |
| Total Liabilities | 57.13M | 250.15M | 451.63M | 1.19B | 1.52B |
| Total Equity | 788.07M | 1.26B | 1.01B | 766.26M | 334.81M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -71.01M | -309.18M | -461.59M | -311.35M | -434.66M |
| Investing | -18.07M | -172.61M | -24.34M | -5.14M | -13.75M |
| Financing | 198.84M | 768.56M | 435.16M | 575.99M | 199.65M |
| Market Cap | 1.09B |
| Price to Earnings Ratio | -0.96 |
| Price to Sales Ratio | 0.37 |
| Price to Cash Ratio | 0.46 |
| Price to Book Ratio | 1.34 |
| Dividend Yield | - |
| Shares Outstanding | 59.57M |
| Average Volume (1 week) | 685 |
| Average Volume (1 Month) | 1.48k |
| 52 Week Change | 153.37% |
| 52 Week High | 18.46 |
| 52 Week Low | 7.195 |
| Spread (Intraday) | 0.17 (0.93%) |
| Company Name | Calliditas Therapeutics AB |
| Address |
kungsbron 1, c8 stockholm SE-111 22 |
| Website | https://www.calliditas.se |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
